{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:55:43Z","timestamp":1789052143757,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-22-CE14-0055-01"],"award-info":[{"award-number":["ANR-22-CE14-0055-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"Magyar Tudom\u00e1nyos Akad\u00e9mia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["ZIA AA000360"],"award-info":[{"award-number":["ZIA AA000360"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["Z1A AA000355"],"award-info":[{"award-number":["Z1A AA000355"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["PD-139012"],"award-info":[{"award-number":["PD-139012"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004618","name":"Universit\u00e9 de Bourgogne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008966","name":"Soci\u00e9t\u00e9 Francophone du Diab\u00e8te","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008966","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.metabol.2025.156291","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T10:57:17Z","timestamp":1747047437000},"page":"156291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Evaluation of tetrahydropyridazine-based peripherally restricted dual inhibitors of CB1R and inducible nitric oxide synthase (iNOS) for treating metabolic syndrome disorders"],"prefix":"10.1016","volume":"170","author":[{"given":"Pinaki","family":"Bhattacharjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szabolcs","family":"Dvor\u00e1csk\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oc\u00e9ane","family":"Pointeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Rutland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Henry","family":"Puhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Godlewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio A.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Jourdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Resat","family":"Cinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malliga R.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2025.156291_bb0005","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.metabol.2025.156291_bb0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/alcalc\/agh110","article-title":"The endocannabinoid system: physiology and pharmacology","volume":"40","author":"de Rodr\u00edguez Fonseca","year":"2005","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.metabol.2025.156291_bb0015","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/1028415X.2017.1347373","article-title":"Polyunsaturated fatty acids and endocannabinoids in health and disease","volume":"21","author":"Freitas","year":"2018","journal-title":"Nutr Neurosci"},{"key":"10.1016\/j.metabol.2025.156291_bb0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.metabol.2025.156291_bb0025","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/febs.12260","article-title":"Modulating the endocannabinoid system in human health and disease: successes and failures","volume":"280","author":"Pacher","year":"2013","journal-title":"FEBS J"},{"key":"10.1016\/j.metabol.2025.156291_bb0030","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/156802608783498005","article-title":"Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors","volume":"8","author":"Vandevoorde","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.metabol.2025.156291_bb0035","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1517\/13543784.9.7.1553","article-title":"Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development","volume":"9","author":"Pertwee","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.metabol.2025.156291_bb0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.54.2.161","article-title":"XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.metabol.2025.156291_bb0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/bs.apha.2017.03.007","article-title":"CB1 and CB2 receptor pharmacology","volume":"80","author":"Howlett","year":"2017","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.metabol.2025.156291_bb0050","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/sj.bjp.0707584","article-title":"CB2 receptors in the brain: role in central immune function","volume":"153","author":"Cabral","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.metabol.2025.156291_bb0055","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/aps.2016.149","article-title":"Brain cannabinoid receptor 2: expression, function and modulation","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.metabol.2025.156291_bb0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1210\/er.2005-0009","article-title":"The emerging role of the endocannabinoid system in endocrine regulation and energy balance","volume":"27","author":"Pagotto","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1016\/j.metabol.2025.156291_bb0065","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.metabol.2018.10.010","article-title":"Pharmacotherapy of obesity: available medications and drugs under investigation","volume":"92","author":"Pilitsi","year":"2019","journal-title":"Metab Clin Exp"},{"issue":"20","key":"10.1016\/j.metabol.2025.156291_bb0070","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despr\u00e9s","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2025.156291_bb0075","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2146\/060258","article-title":"Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity","volume":"64","author":"Patel","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.metabol.2025.156291_bb0080","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/oby.2011.69","article-title":"Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist\/inverse-agonist therapies","volume":"19","author":"Ward","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2025.156291_bb0085","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ejmech.2014.04.011","article-title":"Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists","volume":"79","author":"Sharma","year":"2014","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.metabol.2025.156291_bb0090","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202001960R","article-title":"Peripheral CB1R as a modulator of metabolic inflammation","volume":"35","author":"Han","year":"2021","journal-title":"FASEB J"},{"key":"10.1016\/j.metabol.2025.156291_bb0095","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.2174\/1568026619666190708164841","article-title":"Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: current approaches for therapeutics development","volume":"19","author":"Nguyen","year":"2019","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.metabol.2025.156291_bb0100","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1021\/jm031019q","article-title":"Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists","volume":"47","author":"Lange","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.metabol.2025.156291_bb0105","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1016\/j.bmcl.2005.07.054","article-title":"Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity","volume":"15","author":"Lange","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.metabol.2025.156291_bb0110","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.bmcl.2009.08.007","article-title":"Synthesis and SAR of 1,4,5,6-tetrahydropyridazines as potent cannabinoid CB1 receptor antagonists","volume":"19","author":"Lange","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.metabol.2025.156291_bb0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/14728210902736568","article-title":"Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis","volume":"14","author":"Janero","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.metabol.2025.156291_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107477","article-title":"The therapeutic potential of second and third generation CB1R antagonists","volume":"208","author":"Cinar","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.metabol.2025.156291_bb0125","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bcp.12141","article-title":"Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects","volume":"76","author":"Klumpers","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2025.156291_bb0130","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1016\/j.bmcl.2013.06.066","article-title":"Peripherally restricted CB1 receptor blockers","volume":"23","author":"Chorvat","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.metabol.2025.156291_bb0135","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1021\/acsptsci.1c00048","article-title":"Functional selectivity of a biased cannabinoid-1 receptor (CB1R) antagonist","volume":"4","author":"Liu","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.metabol.2025.156291_bb0140","first-page":"1","article-title":"Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis","author":"Cinar","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.metabol.2025.156291_bb0145","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1021\/acs.jmedchem.6b01504","article-title":"Design, synthesis, and biological evaluation of novel, non-brain-penetrant, hybrid cannabinoid CB1R inverse agonist\/inducible nitric oxide synthase (INOS) inhibitors for the treatment of liver fibrosis","volume":"60","author":"Iyer","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.metabol.2025.156291_bb0150","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s00125-003-1173-x","article-title":"Suppressive effects of a selective inducible nitric oxide synthase (INOS) inhibitor on pancreatic beta-cell dysfunction","volume":"46","author":"Kato","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2025.156291_bb0155","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00125-007-0734-9","article-title":"Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes","volume":"50","author":"Zheng","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2025.156291_bb0160","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrneph.2009.155","article-title":"Selective INOS inhibition for the treatment of sepsis-induced acute kidney injury","volume":"5","author":"Heemskerk","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.metabol.2025.156291_bb0165","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.lfs.2003.10.042","article-title":"INOS-mediated nitric oxide production and its regulation","volume":"75","author":"Aktan","year":"2004","journal-title":"Life Sci"},{"key":"10.1016\/j.metabol.2025.156291_bb0170","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1084\/jem.187.9.1361","article-title":"The multiplex function of nitric oxide in (auto)immunity","volume":"187","author":"Bogdan","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.metabol.2025.156291_bb0175","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/nm1001-1138","article-title":"Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle","volume":"7","author":"Perreault","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2025.156291_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.471","article-title":"CB1 R and INOS are distinct players promoting pulmonary fibrosis in Hermansky-Pudlak syndrome","volume":"11","author":"Cinar","year":"2021","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.metabol.2025.156291_bb0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bph.14849","article-title":"Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease","volume":"177","author":"Udi","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.metabol.2025.156291_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.744857","article-title":"Peripheral hybrid CB1R and INOS antagonist MRI-1867 displays anti-fibrotic efficacy in bleomycin-induced skin fibrosis","volume":"12","author":"Zawatsky","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2025.156291_bb0195","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1124\/mol.115.098541","article-title":"Structural basis of species-dependent differential affinity of 6-Alkoxy-5-Aryl-3-pyridinecarboxamide cannabinoid-1 receptor antagonists","volume":"88","author":"Iyer","year":"2015","journal-title":"Mol Pharmacol"},{"issue":"9","key":"10.1016\/j.metabol.2025.156291_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25095012","article-title":"Pharmacological evaluation of cannabinoid receptor modulators using Grabecb2.0 sensor","volume":"25","author":"Shivshankar","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2025.156291_bb0205","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1021\/acs.jmedchem.1c01836","article-title":"Synthesis, biological evaluation, and molecular modeling studies of 3,4-diarylpyrazoline series of compounds as potent, nonbrain penetrant antagonists of cannabinoid-1 (CB1R) receptor with reduced lipophilicity","volume":"65","author":"Iyer","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.metabol.2025.156291_bb0210","doi-asserted-by":"crossref","first-page":"11985","DOI":"10.1021\/acs.jmedchem.3c00599","article-title":"Cannabinoformins: designing biguanide-embedded, orally available, peripherally selective cannabinoid-1 receptor antagonists for metabolic syndrome disorders","volume":"66","author":"Dvor\u00e1csk\u00f3","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.metabol.2025.156291_bb0215","doi-asserted-by":"crossref","first-page":"10694","DOI":"10.1038\/s41467-024-54206-0","article-title":"Structural mechanism of CB1R binding to peripheral and biased inverse agonists","volume":"15","author":"Kumari","year":"2024","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.metabol.2025.156291_bb0220","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/jlcr.3639","article-title":"Synthesis of 13C6-labeled, dual-target inhibitor of cannabinoid-1 receptor (CB1R) and inducible nitric oxide synthase (iNOS)","volume":"61","author":"Iyer","year":"2018","journal-title":"J Labelled Comp Radiopharm"},{"key":"10.1016\/j.metabol.2025.156291_bb0225","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hep.26606","article-title":"Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides","volume":"59","author":"Cinar","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2025.156291_bb0230","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.118.083279","article-title":"In vitro-in vivo extrapolation of key transporter activity at the blood-brain barrier","volume":"47","author":"Trapa","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.metabol.2025.156291_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22063170","article-title":"PAI-1 in diabetes: pathophysiology and role as a therapeutic target","volume":"22","author":"Altalhi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2025.156291_bb0240","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2337\/db20-0078","article-title":"Simultaneous inhibition of peripheral CB1R and INOS mitigates obesity-related dyslipidemia through distinct mechanisms","volume":"69","author":"Roger","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2025.156291_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417516","article-title":"Role of the CB2 cannabinoid receptor in the regulation of food intake: a systematic review","volume":"24","author":"Rodr\u00edguez-Serrano","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952500160X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952500160X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:47:48Z","timestamp":1778564868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002604952500160X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":49,"alternative-id":["S002604952500160X"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156291","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of tetrahydropyridazine-based peripherally restricted dual inhibitors of CB1R and inducible nitric oxide synthase (iNOS) for treating metabolic syndrome disorders","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"156291"}}